AU4159085A - A peptide vaccine or diagnostic, and a polypeptide useful therefor - Google Patents
A peptide vaccine or diagnostic, and a polypeptide useful thereforInfo
- Publication number
- AU4159085A AU4159085A AU41590/85A AU4159085A AU4159085A AU 4159085 A AU4159085 A AU 4159085A AU 41590/85 A AU41590/85 A AU 41590/85A AU 4159085 A AU4159085 A AU 4159085A AU 4159085 A AU4159085 A AU 4159085A
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- amino acid
- lys
- thr
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title claims description 161
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 151
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 143
- 229940023041 peptide vaccine Drugs 0.000 title claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 57
- 108010000916 Fimbriae Proteins Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 23
- 230000000890 antigenic effect Effects 0.000 claims description 21
- 241000588653 Neisseria Species 0.000 claims description 18
- 206010018612 Gonorrhoea Diseases 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- 230000036046 immunoreaction Effects 0.000 claims description 9
- 208000001786 gonorrhea Diseases 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 2
- 150000007854 aminals Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 229960005486 vaccine Drugs 0.000 description 26
- 239000007790 solid phase Substances 0.000 description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 18
- 239000002054 inoculum Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- IXJYMUFPNFFKIB-FMONCPFKSA-N pomp protocol Chemical compound S=C1N=CNC2=C1NC=N2.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IXJYMUFPNFFKIB-FMONCPFKSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- 229960000814 tetanus toxoid Drugs 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 229940037003 alum Drugs 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 238000006845 Michael addition reaction Methods 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 208000007893 Salpingitis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 108010031071 cholera toxoid Proteins 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000003072 Ellman's test Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241001108452 Neisseria gonorrhoeae MS11 Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000000635 anti-gonococcal effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
A PEPTIDE VACCINE OR DIAGNOSTIC, AND A POLYPEPTIDE USEFUL THEREFOR Description Cross-Reference to Related Application This application is a continuation-in-part of U.S. Serial No. 597,434, filed on 6 April 1984. Technical Field
This invention relates to antigens, immunogens, and to vaccines utilizing such immunogens. More particularly, this invention relates to polypeptide antigens or immunogens, antibodies raised by such immunogens, and a vaccine suitable for the prevention of gonorrhea. Background Art The annual incidence of reported infections by Neisseria gonorrhoeae is estimated to be about two million cases. A gonococcal infection in men usually results in a relatively uncomplicated urogenital infection. Disseminated gonococcal infection is reported to occur in 1 to 3% of those with gonorrhea, but the morbidity of this disease with current therapy is slight.
On the other hand, in women infected with gonorrhea, salpingitis occurs in 10 to 20%, and even when adequately treated, may result in recurrent salpingitis, ectopic pregnancy, and infertility. It is estimated that salpingitis leads to 1.8 million office visits to private physicians and 220,000 hospitalizations each year in the United States. The control of gonorrhea by public health measures to date has been difficult. A vaccine composed of whole, killed gonococci has not been efficacious, Greenburg et al., "Preliminary Studies On The Development Of A Gonococcal Vaccine," Bull. Wld. Hlth. Org. 45:531 (1971). Penicillinase-produc- ing strains of gonococci have also emerged.
ith a view toward developing an efficacious vaccine, several studies have examined surface components of the gonococcus, including lipopolysaccharide (LPS) , peptideglycan, outer membrane proteins, capsules, IgAl protease, and pili. Of the foregoing, pili have been proposed as essential constituents of a gonorrhea vaccine, and it has been reported that pili are immunogenic and nontoxic for humans. See, generally, Schoolnik et al. , "A Pilus Peptide Vaccine For The Prevention Of Gonorrhea," Prog. Allergy 33_:314-331 (1983). The pili are proteinaceous surface appendages of bacteria which promote infectivity by facilitating the attachment of the bacterial cell to host epithelial tissues. In the case of N. gonorrhoeae, the pilus protein is a primary surface antigen. Each pilus is a fimbriak structure composed of repeating identical subunits (pilin) , each having a molecular weight of approximately 18,000 daltons. There are many serotypes of N. gonorrhoeae pili? however, peptide mapping studies of antigenically and immunogenically different pilin indicate that they all share a conserved region located at the amino terminal end of the protein. On the other hand, the carboxy terminal region of the protein has been found to be variable from serotype to serotype. A general description of the pilus protein can be found in Meyer et al.. Cell 30:45:52 (1982).
Schoolnik et al., op. cit., propose an immunogenic pilus peptide that encompasses the conserved region at the amino terminal end of the protein. However, to date, an effective vaccine has not resulted from that particular approach.
In contradistinction to the. foregoing, it has now been found that the variable region of N. gonorrhoeae pilin protein near the carboxy terminal
end of the protein contains both hypervariable sequences as well as conserved sequences defining antigenic determinant sites that can be utilized to prepare antigens and/or immunogens that immunologically mimiσk these antigenic determinant sites, and that elicit antibody production in a mammalian host. Summary Of The Invention
The present invention contemplates a polypeptide that is smaller than a naturally-occurring gonococcal pilin protein, and the pharmaceutically acceptable salts thereof, that are capable of immunologically mimicking a conserved antigenic determinant site within a variable region of the carboxy-terminal half of the gonococcal pilin and thus are capable of being an antigen, or an immunogen, against a gonococcal infection. Additionally, the present invention contemplates a vaccine that contains such an immunogen as well as a method of immunization against a gonococcal infection. This invention further contemplates a diagnostic assay utilizing a polypeptide of this invention and/or a receptor such as an antibody elicited by such a polypeptide. The polypeptide of this invention comprises at least one amino acid residue sequence, containing at least five amino acid residues and up to about 60 amino acid residues, that defines a sequence capable of immunologically mimicking an antigenic determinant site of a gonococcal pilin. This amino acid residue sequence can repeat as a unit one or more times in the same polypeptide molecule. More than one type of such repeating unit, and more than one repeating unit of the same type, can be present in a single polypeptide molecule that embodies the present invention.
Such polypeptide can be made as a fusion protein synthesized by genetic engineering techniques or it can be built-up from individual amino acid residues, or amino acid residue blocks. Polypeptides embodying this invention can be defined as including the amino acid residue sequence, taken from left to right and in the direction from the amino-terminus to the carboxy-terminus, of the formula
wherein X is an amino acid residue having a positively charged side chain and is a member "of the group consisting of histidine (HIS) , lysine (LYS) and arginine (ARG) , X 2 and X3 can be the same or different and are non-polar amino acid residues that are members of the respective groups consisting of leucine (LEU) , proline (PRO) , tryptophan (TRP) , phenylalanine (PHE) , valine (VAL) , alanine (ALA)' and isoleucine (ILE) , and X 4 and X5 can be the same * or different and are polar but uncharged amino acid residues that are members of the respective groups consisting of serine (SER) , threonine (THR) , cysteine
(CYS) and glycine (GLY) ..
Preferred amino acid residue sequences that define a desired antigenic determinant site are
• included in the sequences, taken from left to right and in the direction from the amino-terminus to the carboxy-terminus, of the formula:
-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-; -THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-
LYS-ALA-SER-ASP-ALA-LYS-; and
-GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN-PRO-
•VAL-THR-ARG-, and antigenically related variants thereof. Also preferred are the corresponding polypeptides themselves, that is.
H-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-OH ; H-THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP- LYS-ALA-SER-ASP-ALA-LYS-OH; and
H-GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN-PRO- VAL-THR-ARG-OH, the pharmacologically acceptable salts thereof, and antigenically related variants thereof. Detailed Description Of Preferred Embodiments
Polypeptides of the present invention are smaller than the naturally-occurring gonococcal pilin protein and include an amino acid residue sequence of at least five to about 60 amino acid residues, preferably five to twenty amino acid residues, that immunologically mimicks a conserved antigenic determinant site in the variable region of the carboxy-terminal half of gonococcal pilin protein. As such, the present polypeptides are useful by themselves, or as pharmaceutically acceptable salts, as the active constituent in a vaccine, as an inoculum, or in a diagnostic assay.
The term "antigenic determinant," as used herein, designates the structural component of a molecule that is responsible for specific interaction with corresponding antibody (immunoglobulin) molecules elicited by the same or related antigen. Antigenic determinants in the present polypeptides comprise chemically active surface groupings of amino acid residues.
The term "antigen," as used herein, means an entity that is bound by an antibody.
The term "immunogen," as used herein, describes an entity that induces antibody production in the host animal. In some instances the antigen and the immunogen are the same entity, while in other instances the two entities are different.
The phrase "immunologically mimicks" is used herein to mean that an immunogenic polypeptide of this invention is not a natural protein or a cleaved fragment of a natural protein, but a manufactured polypeptide, as by solid phase synthesis or genetic engineering techniques, which polypeptide induces production of antibodies that bind to the inducing polypeptide and also to a corresponding pilin or pilin polypeptide portion. All amino acid residues identified herein are in the natural or L-configuration unless otherwise specified. In keeping with standard peptide nomenclature, abbreviations for amino acid residues that have been used herein are as follows:
Symbol Amino Acid
1-Letter 3 -Letter
Y TYR - -L-tyrosine
G GLY -glycine
F PHE -L-phenylalanine
M MET -L-methionine
A ALA -L-alanine
S SER -L-serine
I ILE -L-isoleucine
L LEU -L-leucine
T THR -L-threonine
V VAL -L-valine
P PRO -L-proline
K LYS -L-lysine
N ASN -L-asparagine
H HIS -L-histidine
Q GLN -L-glutamine
E GLU -glutamic acid
W TRP -L-tryptophan
R Arg -L-argi ine
D ASP -L-aspartic acid
C CYS -L-cysteine.
The term "pharmaceutically acceptable salts," as used herein, refers to the non-toxic alkali metal, alkaline earth metal and ammonium salts commonly used in the pharmaceutical industry including the sodium, potassium, lithium, calcium, magnesium, and ammonium salts and the like which are prepared by methods well known in the art. The term also includes non-toxic acid addition salts which are generally prepared by reacting the compounds of this invention with a suitable organic or inorganic acid. Representative salts include the hydrochloride, hydrobro ide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, ' succinate, tartrate, and the like.
The polypeptides meeting the foregoing conditions elicit antibodies in a mammalian host and are believed to be capable of forming a beta-turn structure that. ermits the polypeptide to immunologically mimick a desired conserved antigenic determinant site within a variable region of the carboxy-terminal half of the pilin protein. Preferably, the polypeptide is no more than about 60 amino acid residues long and contains in each defined antigenic determinant site at least one amino acid residue having a positively charged side chain.
One or more amino acid residue sequences meeting the foregoing conditions can be present as repeating units. Additionally, polypeptides containing one or more such amino acid residue sequences can be formed into relatively larger synthetic moieties by joining the individual polypeptides head-to-tail or by interpolypeptide cysteine disulfide bonds. These polypeptides can be characterized as
■ those including the amino acid residue sequences.
taken from left to right in the direction from the amino-terminus to the carboxy-terminus, of the formula
-X1-X2-X3-X4-X5- wherein each X designates an amino acid residue. Additionally, X is an amino acid residue having a positively charged side chain such as HIS, LYS or ARG. X 2 and X3 can be the same or different but are non-polar amino acid residues selected from the group consisting of LEU, PRO, TRP, PHE, VAL, ALA and ILE. Similarly, X 4 and X5 can be the same or different but are polar, uncharged amino acid residues selected from the group consisting of SER,
THR, CYS and GLY. The charges referred to above relate to ionic charges on the amino acid residues when those residues are present in an aqueous solution at pH 7.0. See for example, Lehninger, Short Course in Biochemistry, p. 37, Worth Publishers, Inc., New York, New York (1973).
.Particularly preferred amino acid residue sequences within the above grouping, taken from left to right and in the direction from the amino-terminus to the carboxy-terminus, are
-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-; -THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP- LYS-ALA-SER-ASP-ALA-LYS-y and
-GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN-PRO- VAL-THR-ARG-, which sequences have been found to be conserved within the variable region of the carboxy-terminal half of pilin proteins from six different serotypes of N. gonorrhoeae strain MS 11, as described by Meyer et al., Proc. Nat'l Acad. Sci. USA (1984): 81:6110-6114, as well as the antigenically related variants thereof as defined hereinbelow. More than one of the foregoing sequences can be present in the same polypeptide, usually spaced
from one another by a chain of other amino acid residues. In addition, the same polypeptide containing one or more of the foregoing amino acid residue sequences can also include a further amino acid residue sequence that immunologically mimicks an i munorecessive antigenic determinant site of a gonococcal pilin.
Another grouping of preferred polypeptides embodying the present invention, and free from intra-chain (intra-polypeptide) disulfide loops, is represented by polypeptides that are individually constituted by only one of the amino acid residue sequences specifically defined hereinabove, i.e., H-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-OH; .H-THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP- •
LYS-ALA-SER-ASP-ALA-LYS-OH; and
H-GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN-PRO- VAL-THR-ARG-OH.
Biochemical evidence from immunoassay and from analogy with conserved protein-protein interaction in solved X-ray crystallographic structures with differing sequences such as in the dimer contacts of oligomeric enzymes indicates that the conservation of protein-protein recognition does not require a strict conservation of sequence, for relatedness. While single amino acid residue changes may affect such recognition to a wide degree depending upon the nature of the substitution, in general terms the relatedness of two differing amino acid sequences with respect to protein-protein (and antigenic and/or immunogenic) recognition can be expressed in terms of seven basic amino acid parameters:
(1) hydrophobicity; (2) evolutionary occurrence of changes in known sequences;
-IO¬ CS) size of side chain;
(4) charge and polarity;
(5) preference for turned secondary structure; (6) preference for beta strand secondary structure; and (7) preference for helical secondary structure. To define the degree of sequence identity relevant to antigenic and/or immunogenic recognition, and thus antigenically related variants, a consensus matrix can be used to assign numerical values for each amino acid pair in the sequences being considered for relatedness. For the purposes of the present invention, the following consensus matrix, wherein the individual amino acid residues are designated by a one-letter code in the interests of conciseness, can be used: -
A R N D C Q ε G H I K M P P s T w Y ' V
A 7 -5 -1 -2 0 0 -1 2 -1 0 1 -2 2 -1 0 0 0 -3 -3 1
R -5 10 0 -1 -3 2 -1 -5 5 -4 -4 5 -3 -2 -3 0 0 -1 -1 -4
N -1 0 6 3 1 3 0 1 3 -2 -2 2 -1 -3 1 4 2 -3 0 -2
D -2 -1 3 7 -2 1 4 0 0 -3 -3 0 -2 -4 0 1 0 -5 -2 -3
C 0 -3 1 -2 7 1 -2 1 0 0 0 -2 0 0 0 3 4 -2 2 0
Q 0 2 3 1 1 6 2 -1 4 0 0 2 0 0 0 1 • 3 -1 0 0 ε -1 -1 0 - 4 -2 2 7 -3 1 -3 -2 0 -1 -3 -2 0 0 -5 -3 -3
G 2 -5 1 0 1 -1 -3 8 -2 -3 -3 -2 -2 -5 2 3 1 -6 -2 -2
H -1 5 3 0 0 .4 1 -2 8 -1 0 4 0 0 0 1 2 0 2 -1
I 0 -4 -2 -3 0 0 -3 -3 -1 5 4 -3 2 2 -2 -2 0 0 0 4
L 1 -4 -2 -3 0 0 -2 -3 0 4 6 -2 4 3 -1 -2 0 1 0 3
-2 5 2 0 -2 2 0 -2 4 -3 -2 8 -1 -3 -1 0 0 -4 -2 -3
M 2 -3 -1 -2 0 0 -1 -2 0 2 4 -1 6 2 0 -1 0 0 -1 2
F -1 -2 -3 -4 0 0 -3 -5 0 2 3 -3 2 7 -2 -3 0 4 3 2
P 0 -3 1 0 0 0 -2 2 0 -2 -1 -1 0 -2 7 2 1 -4 -1 -1
S 0 0 4 1 3 1 0 3 1 -2 -2 0 -1 -3 2 5 3 -3 0 -1
0 0 2 0 4 3 0 1 2 0 0 0 0 0 1 3 6 -2 1 0 w -3 -1 -3 -5 -2 -1 -5 -6 0 0 1 -4 0 4 -4 -3 -2 9 2 0 ϊ -3 -1 0 -2 2 0 -3 -2 2 0 0 -2 -1 • 3 -1 0 1 2 8 0 v 1 -4 -2 -3 0 0 -3 -2 -1 4 3 -3 2 2 -1 -1 0 0 0 5
Sequence comparison using the foregoing consensus matrix involves the determination of all possible alignments and the subsequent scoring of these alignments by the matrix. Two sequences are then aligned by computing the maximum match score from the consensus matrix. An alignment score in standard deviation units can be determined by taking the difference between the maximum matched score and the average maximum matched score for random permutation of the two sequences and then dividing by the standard deviation of the random score.
For the present purposes, a consensus matrix score greater than three standard deviations (approximately an average value of about 3 per residue) shows significant relatedness at a confidence level of more than 99.7%. This is a restrictive criterion since it gives a frequency of 0.005 for all 5-residue peptides and 0.0014 for all 13-residue peptides occurring in 2222 known protein sequences. Similarly, a consensus matrix score greater than two standard deviations (approximately an average value of abut 2 per residue) shows significant relatedness at a confidence level of more than 95.4%.
To determine relatedness for the purposes of the present invention, the. consensus matrix score is calculated by ascertaining the matrix value for each aligned amino acid residue pair under consideration and then summing the individual values for each such pair. The obtained sum is then compared against the number of standard deviations signifying the desired confidence level. If the obtained sum is greater than the product of the selected number of standard deviations and the number of amino acid residue pairs under consideration, then the amino acid residue sequences being compared are antigenically related to the indicated confidence level.
For example, to ascertain the antigenic relatedness of the amino acid residue sequences - S-TRP-PHE-CYS-GLY- and -ARG-ILE-PHE-CYS-GLY- the consensus matrix yields the following values
Value -LYS- S -ARG- or K & R 5
-TRP- & -ILE- or W & I 0 -PHΞ- & -PHΞ- or F & F 7
-CYS- & -CYS- or C & C 7
-GLY- S -GLY- or G & G 8
Total 27 For antigenic relatedness at the 99.7% confidence level, the consensus matrix score must exceed the number of amino acid residue pairs under consideration times 3, i.e., 5 x 3 or 15. Inasmuch as 27 > 15, the desired antigenic relatedness is indeed present.
For the purposes of the present invention, antigenic relatedness among polypeptides within the scope of the invention preferably is present at least to about 95% confidence level, and more preferably to at least about 99% confidence level.
A mixture of the foregoing polypeptides, including those having antigenically-related regions as defined hereinabove, can also be used to make up a vaccine against or a diagnostic assay for a gonococcal infection, and/or an inoculum for raising antibodies.
Vaccines containing effective amounts of the present polypeptides induce production of antibodies in a sufficient amount to protect the vaccinated individual from infection with gonococcus and thus
prevent gonorrhea. Booster injections can be given if needed.
Thus, the word "vaccine" in its various' grammatical forms is used herein in relation to the protection of a host mammal. The word "inoculum" in its various grammatical forms is used herein to describe a composition containing a polypeptide of this invention as an active ingredient used for the preparation of antibodies that immunologically bind to gonococcal pili. A vaccine and an inoculum may thus contain the identical ingredients, but their uses are different.
The polypeptides suitable as antigens or immunogens, or both, for the present purposes can be produced synthetically or by genetic engineering techniques, and can be in monomeric as well as multimeric forms for use in vaccines, inocula, or as diagnostics. When used in a vaccine or inoculum, the polypeptide may be used alone, as in the case of an 'oligomer or a multimer, or used linked to another carrier. moiety as a conjugate. When used alone as an immunogen, a polypeptide of this invention typically contains a total of about 20 to about 35 amino acid residues. Shorter polypeptides are preferably linked to a carrier.
Particularly useful conjugate carriers include keyhole limpet hemocyanin (KLH) , tetanus toxoid, poly-L-(LYS:GLU) , peanut agglutinin, ovalbumin, soybean agglutinin, bovine serum albumin (3SA) , human serum albumin, and the like.
The synthetic polypeptides utilized herein are preferably coupled to keyhole limpet hemocyanin (KLH) using the following well known method. The KLH carrier is first activated with m-maleimidobenzoyl-N- hydroxysuccinimide ester, and is subsequently coupled
to the polypeptide through a cysteine residue added to the amino-terminus or carboxy-terminus of the polypeptide by a Michael addition reaction, as described in Liu et al., Biochem. 8 : 690 (1979). A polypeptide of this invention may also be coupled to a carrier through different means, and may be coupled to carriers other than KLH as noted before. For example, a polypeptide may be coupled to a tetanus toxoid carrier through free amino groups, using a 0.04 percent glutaraldehyde solution as is well known. See, for example, Klipstein et al. J. Infect. Dis. 147: 318 (1983).
Cysteine residues added at the amino- or carboxy-terminii of the synthetic polypeptide have been found to be particularly useful for forming conjugates via disulfide bonds and Michael addition reaction products, but other methods well known in the art for preparing conjugates can also be used. Exemplary additional binding (linking) procedures include the use of dialdehydes such as glutaraldehyde (discussed above) and the like, or the use of carbodiimide technology as in the use of a water-soluble carbodiimide, e.g. l-ethyl-3-(3-dimethylaminopropyl) carbodiimide, to form amide links between the carrier and polypeptide. As is also well known- in the art, it is often beneficial to link the synthetic polypeptide to its carrier by means of an intermediate, linking group. As noted before, glutaraldehyde is one such linking group.
However, when cysteine is used for linking to the carrier, the intermediate linking group is preferably an m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS) , also discussed before. MBS is typically first added to the carrier by an ester-amide
interchange reaction. Thereafter, the above Michael reaction can be followed, or the MBS addition may be followed by a Michael addition of a blocked mercapto group such as thiolacetic acid (CH3COSH) across the maleimido-double bond. After cleavage of the acyl blocking group, a disulfide bond is formed between the deblocked linking group mercaptan and the mercaptan of the added cysteine residue of the synthetic polypeptide. The choice of carrier is more dependent upon the ultimate intended use of the immunogenic polypeptide than upon the determinant portion of the immunogen, and is based upon criteria not particularly involved in the present invention. For example, if an inoculum is to be used in animals, as for the production of anti-polypeptide antibodies to be used to assay for the presence of gonococcal pilii, a carrier that does not generate an untoward reaction in the particular animal should be selected. If a vaccine against Neisseria gonorrheae is to be used in man, then the overriding concerns involve the lack of immunochemical or other side reaction of the carrier and/or the resulting immunogen, safety and efficacy—the same considerations that apply to any vaccine intended for human use.
The term "manufactured" as used herein means that the polypeptide molecule or polypeptide repeating unit has been built up synthetically by chemical means, i.e., chemically synthesized or by human-mediated biological means, e.g., by genetic engineering techniques. Thus, the manufactured polypeptides embodying the present invention are free from naturally occurring proteins and fragments thereof. The well-known solid phase chemical
synthesis in which blocked amino acid residues are added in a serial manner to obtain the desired polypeptide is the preferred method of synthesis, and is discussed in greater detail hereinbelow. As mentioned hereinabove, polypeptides suitable for the purposes of the present invention can be synthesized by the well-known solid phase method. See, for example, Houghten et al.. Int. J. Pept. Proc. Res. 16_:311-320 (1980), and Merrifield, J. Am. Chem. Soc. 85_:2149-2154 (1963)., which disclosures are incorporated herein by reference. The solid phase method of polypeptide synthesis can be practiced utilizing a Beckman Model 990B Peptide Synthesizer, available commercially from Beckman Instruments Co., Berkeley, CA, U.S.A.
In preparing a synthetic polypeptide of this invention by the above solid phase method, the amino acid residues are linked to a resin (solid phase) through an ester linkage from the carboxy-terminal residue. When the polypeptide is to be linked to a carrier via a CYS residue, it is convenient to utilize that CYS residue as the carboxy-terminal residue that is ester-bonded to the resin.
The alpha-a ino group of each added amino acid typically is protected by a tertiary-butoxycarbonyl (t-BOC) group prior to the - amino acid being added into the growing polypeptide chain. The t-BOC group is then removed prior to addition of the next amino acid to the growing polypeptide chain. Reactive amino acid side chains are also protected during synthesis of the polypeptide. Usual side-chain protecting groups used for the remaining amino acid residues are as follows: 0-(p_-bromobenzyoxycarbonyl) for tyrosine, O-benzyl for threonine, serine, aspartic acid and
glutamic acid, and S-methoxy-benzyl for cysteine. Protected amino acids are recrystallized from appropriate solvents to give single spots by thin layer chromatography. Couplings are typically carried out using a ten-fold molar excess of both protected amino acid and dicyclohexyl carbodiimide over the number of milliequivalents of initial N-terminal amino acid. A two molar excess of both reagents can also be used. For asparagine, an equal molar amount of N-hydroxy-benzotriazole is added to the protected amino acid and dimethyl-formamide is used as the solvent. All coupling reactions are typically more than 99% complete by the picric acid test of Gisin, Anal. Chem. Acta, Si8_:248-249 (1972). A portion of the resulting, protected, resin-bonded polypeptide (1 gram) is treated with two milliliters of anisole, and anhydrous hydrogen fluoride, 20 milliliters, is condensed into the reaction vessel at dry ice temperature. The resulting mixture is stirred, at 4° for 1.0 hour to cleave the protecting groups and remove the polypeptide from the resin. After evaporating the hydrogen fluoride at a temperature of 4°C. with a stream of j, the residue is extracted with anhydrous diethyl ether three times to remove the anisole, and the residue is dried in vacuo.
The vacuum dried material is first extracted with 5% aqueous acetic acid (3 times 50 milliliters each) followed by extractions using 50% aqueous acetic acid (4 times 50 milliliters). The first extraction removes low molecular weight polypeptides and tyrosine that is used in some preparations to protect the CYS mercapto groups. The second extraction separates the free polypeptide from the resin. After dilution with water to a concentration
of 10-20% acetic acid, the resulting solution is lyophilized to provide a monomeric, unoxidized, polypeptide.
Polypeptide multimers can be prepared by bonding together the synthesized polypeptide monomers in a head-to-tail manner using the aforementioned solid phase method, i.e., one complete polypeptide sequence can be synthesized on the resin, followed by one or more of the same or different polypeptide sequences, with the entire multimeric unit thereafter being cleaved from the resin and used as described herein.
Alternatively, synthesized polypeptide monomers that contain added cysteine residues at both the amino- and carboxy-termini (diCYS polypeptides) can be bonded together by intramolecular, interpolypeptide cystine disulfide bonds utilizing an oxidation procedure to form an immunogenic polymer. The polymer so prepared contains a plurality of the polypeptides of this invention as repeating.units. Those repeating units are bonded together by the above-discussed oxidized cysteine residues.
The presence of one or two terminal CYS residues in a polypeptide of this invention for the purposes of binding the polypeptide to a carrier or preparing a polymer is not to be construed as altering the amino acid sequence of the polypeptide repeating units from a sequence that immunologically mimicks an antigenic determinant site of a gonococcal pilin.
In a typical laboratory preparation, 10 milligrams of the diCYS polypeptide (containing amino- and carboxy-terminal cysteine residues in un-oxidized form) are dissolved in 250 milliliters of
0.1 molar ammonium bicarbonate buffer having a pH value of about 8. The dissolved diCys polypeptide is then air oxidized by stirring the resulting solution gently for a period of about 18 hours, or until there is no detectable free mercapton by the Ellman test. [See, Ellman, Arch. Biochem. Biophys. 8_2_: 70-77 (1959).] The polymer so prepared is then typically isolated by freeze drying, redissolution and chromatographic purification. Typical procedures for the preparation of fusion proteins by genetic engineering techniques are described by Berman, BioTechniques 1.(4) :178-183 (1983), Silhavy et al.. Microbiological Reviews £7(3) :313-344 (1983), and Young et al., Proσ. Natl. Acad. Sci. USA ^0:1194-1198 (1984).
The present vaccines and inocula include one or more of the polypeptides described hereinabove together with a pharmaceutically acceptable diluent such as physiological saline, phosphate-buffered saline (PBS), or other injectable liquid. Additives customarily used in vaccines or inocula may also be present, if desired. Illustrative of such additives are stabilizers such as lactose or sorbitol, and adjuvants such as aluminum hydroxide, sulfate or phosphate, an alum, or an alginate. Precipitated aluminum phosphate (A1P0.) is a particularly suitable adjuvant for a vaccine, while complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) are preferred for use in inocula. Vaccines and inocula of the present invention may be administered by injection, usually intramuscularly or subcutaneously, orally by means of an enteric capsule or tablet, as a suppository, as a nasal spray, and by other suitable routes of administration. For a human patient, a suitable dose
of the polypeptide depends, in part, upon the chosen route of administration and a number of other factors. Included among those factors are the body weight of the mammal to be immunized, the carrier when used, the adjuvant when used, and the number of innoculations desired to be used.
Individual innoculations for a human patient typically contain unit doses of about 10 micrograms to about 100 milligrams of polypeptide, exclusive of any carrier to which the polypeptide may be linked. If desired, a series of doses may be administered over a period of time for optimum immunity. Unit dosage forms of the vaccine can also be provided, if desired, containing the aforementioned amounts,of the polypeptide.
In any event, the immunogen contained in a vaccine or an inoculum is present in an "effective amount," which amount depends upon a variety of factors as is well known in the immunological arts, e.g., the body weight of the mammal to be immunized, the carrier moiety used, the adjuvant used, the duration of protection sought, and the desired immunization protocol.
Whole antibodies, as well as substantially whole antibodies, raised to the polypeptides of this invention and antibody combining sites prepared from such antibodies constitute still another aspect of this invention. These molecules are collectively referred to as receptors. Receptors are raised in mammals such as rabbits, goats, horses and the like by immunization using the inocula described hereinbefore. Immunization procedures are substantially the same as those used in vaccinations except that powerful adjuvants such as CFA and/or IFA that are not
acceptable for human use can be included in animal inocula.
Typical inoculum stock solutions are prepared with CFA, IFA or alum as follows: An amount of the polypeptide, synthetic polypeptide-conjugate or polymeric polypeptide sufficient to provide the desired, effective amount of polypeptide per inoculation is dissolved in PBS at a pH value of 7.2. Equal volumes of CFA or IFA are then mixed with the polypeptide solution to provide an inoculum containing polypeptide, water and adjuvant in which the water-to-oil ratio is about 1:1. The mixture is thereafter homogenized to provide the inoculum stock solution. When alum is used, about 200 micrograms of conjugate is absorbed onto about 4 milligrams of alum to prepare the stock inoculum.
Rabbits can be utilized herein to raise • anti-polypeptide antibodies. When so used, the host rabbit is typically injected subcutaneously with an inoculum comprising 200 micrograms of a polypeptide conjugate (polypeptide plus carrier) emulsified in CFA; 200 micrograms of polypeptide conjugate in IFA; and 200 micrograms of polypeptide conjugate with 4 milligrams alum injected intraperitoneally on days 0, 14 and 21, respectively, of the immunization schedule. Each inoculation (immunization) consists of four injections of the inoculum. Mice may be immunized in a similar way using about one tenth of the above dose per injection. Animals are typically bled 4 and 15 weeks after the first injection. Control pre-immune serum is obtained from each animal by bleeding just before the initial immunization.
Control inoculum stock solutions can also be prepared with keyhole limpet hemocyanin (KLH) , KLH in
CFA or IFA, KLH-alum absorbed, KLH-alura absorbed-pertussis, edestin, thyroglobulin, tetanus toxoid, tetanus toxoid in IFA, cholera toxoid and cholera toxoid in IFA, and the like. The efficacy of the above immunization procedure is typically determined by means of an ELISA in which the immunogenic polypeptide of this invention is used as the antigen to determine the amount of antibodies present in diluted sera obtained from the above bleeds. Sera that provide anti-polype tide antibody titers (dilutions) of at least about 1:160 are considered useful in providing the antibodies of this invention. The typically utilized ELISA is described in greater detail in Bittle et al.. Nature .298: 30-33 (1982), which is incorporated herein by reference.
Suitable monoclonal receptors, typically whole antibodies, may also be prepared using hybridoma 'technology as described by Niman et al., Proc. Natl. Acad. Sσi., USA 80_: 4949-4953 (1983), which description is incorporated herein by reference. Monoclonal receptors need not only be obtained from hybridoma supernatants, but may also be obtained in generally larger quantities from asσites fluid of mammals into which the desired hybridoma has been introduced. Production of monoclonal antibodies using ascites fluid is well known and will not be dealt with further herein.
A receptor of this invention binds both to the polypeptide to which it was raised and also to the corresponding pilin protein whose antigenic determinant site the polypeptide of this invention immunologically mimmicks. Thus, a polypeptide of this invention may be both an immunogen and an antigen.
The receptors of this invention are at least oligoclonal as compared to naturally occur ng polyclonal antibodies since they are raised to an immunogen having relatively few epitopes as compared to the epitopes of an intact pilin molecule.
Consequently, receptors of this invention bind to epitopes of the polypeptide while naturally occurring antibodies raised to a gonococcal pilin bind to epitopes throughout the pilin molecule. The polypeptides, antibodies, and antibody combining sites provided by these polypeptides, and methods of the present invention may also be used for diagnostic tests, such as immunoassays. Such diagnostic techniques include, for example, enzyme immune assay, enzyme multiplied immunoassay technique (EMIT) , enzyme-linked immunosorbent assay (ELISA) , radio-immune assay (RIA) , fluorescence immune assay, either single or double antibody techniques, and other techniques in which either the antibody combining site or the. antigen is labeled with some detectable tag. See generally Maggio, Enzyme Immunoassay, CRC Press, Cleveland, Ohio (1981) , and Goldman, M., Fluorescent Antibody Methods, Academic Press, New York, N.Y. (1980). An illustrative diagnostic system embodying the present invention to detect N. gonorrhoeae contains receptor molecules such as antibodies, substantially whole antibodies, or antibody combining . sites, raised to a polypeptide of this invention. The system also includes an indicating means for signaling the presence of an immunoreaction between the receptor and the antigen. The indicating means allows the immunoreaction to be detected. When admixed with a body sample such as a cervical or urogenital smear, the receptor molecule immunoreacts
with the pilin antigen to form an immunoreactant, and the indicating means present then signals the immunoreaction.
One such exemplary embodiment is an immunofluorescent assay in which a cervical or urogenital smear is acetone-fixed to a plain microscope slide. An aliquot of antibodies raised in accordance with this invention, e.g., raised in rabbits, generally about 10 micrograms to about 500 micrograms, is incubated on the slides using well-known techniques.
After rinsing away any un-immunoreacted antibodies and blocking non-specific binding sites on the slide with a protein such as BSA, a second antibody, such as a goat-antirabbit antibody can then incubated on the test slide, if desired. The second antibody is labeled by being linked to a fluorochrome dye such as fluorscein isothiocyanate (FITC) .
After this second incubation, any excess of the second antibody is rinsed off leaving any
FITC-labeled goat-antirabbit antibodies that bound to the first antibodies on the test slide. Presence of the FITC-labeled antibodies may be detected using fluorescent microscopy and thereby signal the presence of a N. gonorrhoeae infection.
The use of whole, intact, biologically active antibodies for the receptor molecules is not necessary in many diagnostic systems such as the immunofluorescent assay described above. Rather, only the immunologically active, idiotype-containing, antigen binding and recognition receptor site; i.e. the antibody combining site, of the antibody molecule may be used. Examples of such antibody combining sites are those known in the art as Fab and F(ab')2 antibody portions that are prepared by methods well known in the art.
Another diagnostic method of this invention is an ELISA assay. Here, a polypeptide antigen of this invention is bound on a solid support such as the walls of a microtiter plate. Non-specific binding sites on the microtiter well walls are thereafter blocked with a protein such as BSA. Un-bound polypeptide and BSA are removed from the microtiter well as by rinsing.
A body sample such as those above is admixed with an excess of an antibody of this, invention in an aqueous solution, and the admixture is maintained for a -time sufficient to form an immunoreaction between the antibody and any gonococcal pili antigen present. That liquid admixture is then mixed with the above-described polypeptide-bound solid support to form a second admixture containing solid and liquid phases. The solid/liquid phase admixture is maintained for a time sufficient for previously unreacted antibodies to immunoreact with the polypeptide antigen. The liquid phase is thereafter separated from the solid phase.
A solution of a second, labeled antibody that reacts with the first-named antibody is then admixed with the solid phase. An examplary second antibody is a peroxidase-linked goat anti-rabbit antibody where the first-named antibodies are raised in rabbits. The admixture formed from the solid phase and the second, labeled antibody solution is maintained for a time period sufficient to form an immunoreaction between the two antibodies. The solid and liquid phases are thereafter separated.
A solution containing a substrate for the enzyme such as hydrogen peroxide and a color-forming dye precursor such as o-phenylenediamine is thereafter admixed with the solid phase. The optical
density at a preselected wave length (e.g., 405 nanometers) may then by determined after a predetermined time period has elapsed and compared to the optical density of a control to determine whether the gonococcal antigen was present in the body sample.
The present invention is further illustrated by the following detailed examples.
EXAMPLE 1: Polypeptide Synthesis
A series of short synthetic polypeptides whose amino acid residue sequences correspond to small segments of the gonococcal pilin protein were synthesized accordig to the method of Merrifield, J. Am. Chem. Soc, 85_:2149-2154 (1963), as modified by Houghten et al.. Int. J. Pept. Proc. Res., 16:311-320 .(1980), using a Beckman Model 990B Peptide - Synthesizer (Beckman Instruments Co., Berkeley, CA, U.S.A.). The polypeptide designations and the location in the gonococcal pilin protein of their corresponding amino acid- residue sequences are shown in Table 1, below.
TABLE 1 Synthetic Polypeptides Corresponding to Gonococcal Pilin Segments
2
Designation Location Amino Acid Residue Sequence
441 140-159 KEIDTKHLPSTCRDKASDA G GCC44-11- 1 14455--115533 KHLPSTCRD
GC51 144-159 TKHLPSTCRDKASDAK
GC61 115-127 GSVKWFCGQPVTR
1 = polypeptides coupled to tetanus toxoid using the glutaraldehyde procedure described in Example 2.
2 = location corresponds to the amino acid residue positions of the gonococcal pilin protein sequence described by Meyer et al., Proσ. Nat'l Acad. Sci. USA (1984) .81:6110-6114.
EXAMPLE 2: Polypeptide-Carrier Couplings
Polypeptide conjugation to tetanus toxoid carrier using the gluteraldehyde method was performed by admixing equal amounts of peptide and tetanus toxoid in PBS to final concentrations of 2 mg/ml. When difficulty in dissolving a particular peptide was encountered, the pH value of the produced admixture was raised to about 8.0.
A fresh glutaraldehyde working dilution was prepared prior to each coupling by diluting a 25% (w/v in PBS) glutaraldehyde stock solution 1:65 in ice cold PBS. The fresh glutaraldehyde solution was then added to the above obtained peptide-carrie.r- solution at a ratio of 124 microliters to 1 milliliter, respectively. The resulting reaction composition was incubated with stirring overnight at room temperature.
After incubation, the reacation product was dialyzed for at least 6 hours against distilled H20, and then lyophilized.
EXAMPLE 3: Screening of Rabbit Sera for Anti-Polypeptide Antibodies Rabbit anti-sera were screened for the presence of anti-polypeptide antibodies using an enzyme linked i munosorbent assay (ELISA) . Polypeptide antigen made as described in Example 1, above, was adsorbed onto the walls of microtiter plate wells to provide solid phase bound target antigen.
To prepare solid phase bound polypeptide, 25ιl of 0.1%- (w/v) BSA/PBS containing approximately 5 picomoles of polypeptides was placed in a microtiter plate well and incubated at 37°C. until complete evaporation. Polypeptide antigen thus deposited was fixed to the solid phase by incubating 5Qμl of ethanol in each well for 5 minutes at room temperature. After incubation, methanol was removed by inverted shaking and allowing the plates to air dry for 5-10 minutes.
Non-specific binding sites on the microtiter well walls were threafter blocked by incubating 50^1 of 3% (w/v) BSA/PBS in each well for 4 hours at 37°C. in a humidified chamber. After incubation, excess BSA was removed by inverting and shaking the plates. Polypeptide bound to a solid support whose non-specific binding sites had been blocked was thus provided for use as target antigen.
To" assay the rabbit sera for the presence of anti-polypeptide antibodies, an alioquot of each serum was serially diluted two-fold in 1% (w/v) BSA/PBS. Twenty-five microliters of each dilution was contacted with solid phase bound polypeptide by admixture in the appropriate microtiter wells prepared above. Contact was maintained by incubating the wells for about 16 hours at 37°C. in a humidified chamber, thus allowing any anti-polypeptide antibodies present in the serum dilutions to immunoreact with solid phase bound polypeptide target antigen. After incubation, the solid and liquid phases were separated by filling the wells with distilled water, inverting and shaking 10 times in seriatim.
To detect the presence of an immunorecation between anti-polypeptide antibodies and solid-phase
antigen, 25 l of goat anti-rabbit IgG labeled with peroxidase as an indicating means (Boehringer Mannheim Biochemicals, Indianapolis, Indiana) were admixed in each well. After incubation for 1.5 hours at 37°C. in a humidified chamber, the wells were washed 10 times with distilled water as previously described. Fifty microliters of developer solution [55mg of ABTS [2,2'-azino-di- (3-ethylbenzthiazoline sulfonate) ; Boehringer Mannheim]] and lOOil of 30% H2°2 dissolved in 100 ml of 0.1 sodium citrate
(pH 4.2) were then admixed and incubated in each well for about 45-60 minutes at room temperature. The indicating reaction was stopped by admixing 50ul of 5% (w/v) sodium dodecylsulfate (SDSJ/HjO in each well. The amount of indicating reaction (color development) was quantitated by measuring the absorbance of each well at 414 nm.
Rabbit antisera demonstrating a 4-fold higher titer than the negative control were considered positive for the presence of anti-polypeptide antibodies. Antibodies that immunoreact with their inducing polypeptide were raised in rabbits to all the peptides shown in Table 1, above.
EXAMPLE 4: Western Blot Assay
The rabbit antisera were further screened to determine their ability to immunoreact with gonococcal pilin protein in a Western blot assay. Gonococcal pilin protein was isolated from the
N. gonorrhoeae strain MS-11 (described in Meyer et al., supra) by the procedure outlined below.
N. gonorrhoeae MS-11 was plated and grown to confluency on GCB base medium (Diffco Co., Detroit, MI) in 15X100 mm petri dishes (American Scientific Products, McGaw, IL) . The cultures from 50 dishes
were swabbed into 35 ml of 50mM ethanolamine, pH 10.5. The pili were sheared from the bacteria by vortexing for 30 seconds and immersing for 30 seconds in a 0°C. bath 4 times in seriatim. The sheared pili were separated from the bacteria by centrifugation at 10,000 rpm for 20 minutes in a JA20 rotor (Beckman Instruments, Fullerton, CA) . The supernatant containing pilin protein was then dialyzed against pili buffer (.15M NaCl, 0.05M Tris, pH 7.5) for about 16 hours. During dialysis a majority of the pilin protein present formed insoluble aggregates. These aggregates were subsequently isolated by centrifugation at 10,000 rpm for 15 minutes in the above-described rotor. The pilin protein pellet was then resuspended to a concentration of 1 mg/ l in 50mM ethanolamine, pH 10.5. The pilin was further isolated by' eletrophoresis in a 15% SDS-polyacrylamide gel, and transferred to nitrocellulose (Schleicher & Schuel, ' Catalogue No. BA85, Keene, N.H.) using an electro-blotting apparatus (CBS Scientific, Del Mar, CA) , with transfer buffer consisting of 25mM Tris, 192mM glycine, 20% methanol and 0.01% NaN3.
The gonococcal pilin protein bound to the nitrocellulose solid support (Western blot) thus obtained was then used as target antigen in a Western blot assay to detect anti-pilin antibodies.
The rabbit anti-polypeptide antisera were diluted approximately 1:100 in 3% (w/v) BSA/PBS or BLOTTO [PBS containing 50 g/1 nonfat dry milk, 0.1 ml/1 antifoam A emulsion (Sigma Chemical Co., St. Louis, Mo.) and 1 ml/1 thimerosal] . A Western blot was then incubated in 25 ml of each diluted antiserum for about 16 hours at 4°C. with constant agitation so as to contact the anti-polypeptide antibodies present
in the antiserum with the solid phase bound pilin protein.
After incubation, the blots were washed twice with 25 ml of TBS buffer (0.9% NaCl, lO M Tris, pH 7.4) containing 0.5% octylphenoxy polyethoxy ethanol (Triton X100) , washed three times with 25 ml of TBS alone, and then washed with 25 ml of 3% (w/v) BSA/TBS.
Anti-polypeptide antibodies bound to gonococcal pilin protein were detected by first reacting the blots with peroxidase labeled goat anti-rabbit IgG (Boehringer Mannheim) diluted about 1:2000 in 3% (w/v) BSA/TBS or BLOTTO for 16 hours at 4°C. with constant agitation. The blots were then washed as previously described and developed by incubation with 25 ml of the ABTS developing solution described in Example 3, above, for about 45-60 minutes.
The Western blot assay results indicate that all of the anti-polypeptide antisera raised in rabbits immunized with the polypeptides shown in Table 1 also contained antibodies that immunoreact with the gonococcal pilin protein.
EXAMPLE 5: Neisseria ELISA
The anti-polypeptide antibodies that immunoreaσted with gonococcal pilin protein in the Western blot assay of Example 4, above, were examimed for their ability to immunoreact with whole bacteria used as solid phase target antigen in an ELISA.
Eleven strains of Neisseria, including ten pathogenic gonococcal strains (Table 2, below) were obtained from J. Knapp, Neisseria Reference Lab, Seattle, WA. The strains were grown on GC chocolate agar at 35°C. in a 5% CO2 humidified incubator and confirmed by
Gram stain, oxidase reaction, colony morphology and sugar fermentation patterns as is well known in the art.
TABLE 2
Strains Tested
Strain NRL # Description
7122 x. qonorrhoeae POMP 1*
8658 * qonorrhoeae POMP 2
7929 x gonorrhoeae " POMP 3
6611 Hi qonorrhoeae POMP 4
5767 LL gonorrhoeae POMP 5
8035 li qonorrhoeae POMP 6
5766 N. qonorrhoeae POMP 7
8038 Si qonorrhoeae POMP 8
8660 Ni qonorrhoeae POMP 9
1955 . N.. qonorrhoeae Will
9206. ∑i meningitidis B
Neisseria antigen stocks were prepared by swabbing cultures propagated as described above into PBS (pH 7.4). The optical density of each bacterial suspension was then adjusted to 0.1 at 750 nm with PBS (pH 7.4), aliquoted and frozen.
Solid phase bound Neisseria antigen was prepared by adding 50ul of Neisseria stock suspension to microtiter ("Immulon 1" stripwells) . The bacteria were pelleted from solution onto the walls of the wells by centrifugation for 5 minutes at 1000 g in a 4°C. tabletop centrifuge.
After centrifugation, the Neisseria antigen was crosslinked to the solid phase by admixing 200^μl of 0.25% glutaraldehyde in PBS at 4°C. in each well. After a 5 minute incubation at 4°C, the wells were
washed 4 times with PBS. Non-specific binding sites were blocked by incubating 350ul of 5% BSA/PBS containing 0.05% polyoxyethylene (20)sorbitan monolaurate ("Tween 20") for 2 hours at 37°C. in each well. The BSA blocking solution was subsequently removed by aspiration, thus providing Neisseria as target antigen bound to the walls of microtiter wells.
Rabbit antipolypeptide antisera to be examined for anti-Neisseria activity were serially diluted two-fold in 1% (w/v) BSA/PBS. 200
Milliliters of each dilution were adm'ixed in a well prepared as described above forming a solid/liquid phase immunoreaction composition. Contact was maintained by incubating the wells for 1 hour at 37°C, thus allowing the anti-polypeptide antibodies present in the serum dilutions to immunoreact with solid phase bound Neisseria antigen. After incubation, the solid and liquid phases were separated by subjecting the wells to three one-minute washes with PBS containing 0.05% "Tween 20."
Anti-polypeptide antibodies immunologically bound to the solid phase Neisseria were detected with a peroxidase-labeled goat anti-rabbit IgG indicating means obtained from Cappel, A Division of Cooper Biomedical, Malvern, PA. The goat anti-rabbit IgG was diluted 1:2000 in 1% (w/v) BSA/PBS and 200 l were admixed in each well. The admixture was incubated for 1 hour at 37°C. thereby allowing immunoreaction between the goat anti-rabbit IgG antibodies and any rabbit anti-polypeptide antibodies present as bound to the solid phase Neisseria. After incubation the wells were washed five times for one minute each as described above.
The presence of goat anti-rabbit IgG antibodies bound to rabbit anti-polypeptide-Neisseria
immunoreaction products were detected by providing ό-phenylenediamine as peroxidase substrate. Two hundred microliters of O-phenylenediamine developing solution (ODSI-Carpinteria, Carpinteria, CA) were admixed in each well and incubated for 30 minutes at room temperature. The color developing reaction was stopped by adding 50/αl of 2N HC1 to each well. The amount of inicating reaction present was immediately quantitated by measuring the absorbance of each well at 490nm using a Dynatech ELISA plate reader. The above described ELISA was used to examine the anti-gonococcal pilin polypeptide antibodies for their ability to (1) differentiate between pathogenic and commensal Neisseria species; and (2) immunoreact with members of a representative panel of N^ gonorrhoeae pathogenic strains.
In the first series of experiments, the anti-polypeptide antibodies were immunoreacted against the pathogenic ^ qonorrhoeae strain POMP 1 serovar (NRL 7122) and the commensal N^ meningitidis B strain (NRL 9206). The ability to differentiate between the pathogenic and commensal strains was then examined by calculating the ratio of the absorbance produced in the pathogenic strain ELISA versus the absorbance in the commensal strain ELISA. The results of examining the anti-polypeptide antibodies by this procedure are shown in Table 3, below.
TABLE 3 Rabbit Anti-N. Gonorrhoeae
Pilin Peptide Specificity Study
Rabbit ABS at 490nm
Peptide Antisera N. gonorrhoeae N. meningitidis B
ID No. ID No. (Strain 7122) (Strain 9206) Rati
— 94312 0.037 0.136 —
— 94322 0.068 0.013 —
44 T44 0.848 0.599 1.4
GC4 GC4-9307 0.661 0.324 2.0
GC4 GC4-9309 0.239 0.283 0.8
GC6 GC6-9310 0.274 0.119 2.3
1 = ratio of N. gonorrhoeae/N. meningitidis Absorbainee
Values; Antisera Dilution 1:3200. 2 = negative controls
As can be seen from the foregoing Table 3, antibodies induced by polypeptides made in accordance with the present invention, especially antibodies to polypeptides GC4 and GC6, as shown in Table 1, demonstrate significant immunospecificity for the pathogenic ^ qonorrhoeae strain as opposed to the commensal ^_ meningitidis strain. The polypeptides of the present invention are suitable vaccine and inocula components because they direct the host's immune response towards disease-producing Neisseria species. The second series of experiments utilizing the Neisseria antigen ELISA examined the ability of anti-polypeptide antibodies made in accordance with the present invention to immunoreact with members of a representative panel of N^ gonorrhoeae pathogenic strains. The results of these experiments, shown in
Table 4, below, indicate that antibodies raised to the preferred polypeptides GC4 and GC6 have broad immunospecificity for pathogenic N^ qonorrhoeae strains. Antiserum GC4-9307 contained a sufficient titer of anti-polypeptide antibodies to be able to recognize 9 out of the 10-pathogenic strains screened (i.e., all but NRL 8035) when used at a 1:1600 dilution and compared to the pre-immune control serum. Similarly, antiserum GC6-9310 recognized 7 out of the 10 pathogenic strains (i.e., all but NRL 8035, NRL 5766 and NRL 8038) at a 1:1600 dilution.
TABLE 4 Rabbit Antisera vs. Neisseria Panel
Strain ABS at 490nm1
NRL No. GC4-9307 GC6-9310 94322
7122 • 0.678 0.133 0.021
8658 0.541 0.229 0.003
7929 0.616 0.205 0.
6611 0.697 0.197 0.060
5767 0.659 0.191 0.098
8035 0.690 0.243 0.843
5766 >1.5 0.231 0.302
8038 1.069 0.169 0.220
8660 0.833 0.273 0.12
1955 0.550 0.220 0.084
9206 0.626 0.120 0.020 _
1 = antisera dilution 1:1600
2 = control antiserum
The range of pathogen strain immunospecificity (cross reactivity) demonstrated by
the results in Table 4, above, indicate that the polypeptides of the present invention induce broad spectrum antibodies. The ability to induce broad spectrum antibodies is a very desirable element in vaccine design because many pathogens, including N. gonorrhoeae escape destruction by a host's immune system through antigenic (strain) variation. The results in Table 4 therefore further demonstrate the utility of the polypeptides of the present invention for use as components in broad spectrum N. qonorrhoeae vaccines.
Claims (17)
1. A polypeptide which is smaller than a naturally occurring gonococcal pilin protein, which includes an amino acid residue sequence constituted by at-least five amino acid residues and up to about 60 amino acid residues, and which is capable of immunologically mimicking a conserved antigenic determinant site within a variable region of the carboxy-terminal half of a gonoccoccal pilin. 2. A polypeptide containing no more than about 60 amino acid"residues and including the amino acid residue sequence, taken from left to right in the direction from amino-terminal to the carboxy-terminal, of the formula
1 2 3 4 5 -X -X -X -X -X - wherein X is an amino acid residue having a positively charged side chain and is a member of the group consisting of HIS, LYS, and ARG, X 2 and X3 are same or different non-polar amino acid residues that are members of the group consisting of LEU, PRO, TRP, PHE, VAL, ALA and ILE, and X4 and X5 are same or different polar, uncharged amino acid residues that are members of the group consisting of SER, THR, CYS and GLY; and pharmaceutically acceptable salts thereof.
3. The polypeptide in accordance with claim 2 wherein X1 is HIS, X2 is LEU, X3 is PRO, X4 is SER, and X5 is THR.
4. The polypeptide in accordance with claim 2 wherein X1 is LYS, X2 is TRP, X3 is
PHE, X4 is CYS, and X5 is GLY.
5. The polypeptide in accordance with claim 2 and including the amino acid residue sequence
-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-.
6. The polypeptide in accordance with claim 2 and including the amino acid residue sequence -THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP- -LYS-ALA-SER-ASP-ALA-LYS-.
7. The polypeptide in accordance with claim 2 and including the amino acid residue sequence -GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN- -PRO-VAL-THR-ARG.
8. A polypeptide represented by the formula H-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-OH and a pharmaceutically acceptable salt thereof.
9. A polypeptide represented by the formula H-THR-LYS-HIS-LEU-PRO-SER-THR-CYS-ARG-ASP-
-LYS-ALA-SER-ASP-ALA-LYS-OH and a pharmaceutically acceptable salt thereof.
10. A polypeptide represented by the formula H-GLY-SER-VAL-LYS-TRP-PHE-CYS-GLY-GLN-
-PRO-VAL-THR-ARG-OH •and a pharmaceutically acceptable salt thereof.
11. A peptide vaccine suitable for the prevention of gonorrhea which comprises a pharmaceutically acceptable diluent and a polypeptide defined by claim 1.
12. A peptide vaccine in accordance with claim 11 in unit dosage from wherein the polypeptide is present in an amount of about 10 micrograms to about 100 milligrams.
13. A method of immunizing against a gonococcal infection a susceptible patient which method comprises administering to the patient a pharmaceutically acceptable diluent and an effective amount of polypeptide defined by claim 1.
14. A diagnostic system suitable for assaying for Neisseria qonorrhoeae pilus protein which system comprises (a) receptor molecules elicited in an aminal host by the polypeptide defined in claim 1 and (b) indicating means capable of signaling an immunoreaction of said receptor molecules with the pilus protein.
15. A receptor raised to the polypeptide defined by claim 1.
16. The receptor in accordance with claim 15 wherein the receptor is a whole antibody.
17. The receptor in accordance with the claim 15 wherein the receptor is an antibody combining site.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59743484A | 1984-04-06 | 1984-04-06 | |
US597434 | 1984-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4159085A true AU4159085A (en) | 1985-11-01 |
AU582358B2 AU582358B2 (en) | 1989-03-23 |
Family
ID=24391484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU41590/85A Ceased AU582358B2 (en) | 1984-04-06 | 1985-04-04 | A peptide vaccine or diagnostic, and a polypeptide useful therefor |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0177583A4 (en) |
JP (1) | JPS61501777A (en) |
AU (1) | AU582358B2 (en) |
FI (1) | FI81452C (en) |
IL (1) | IL74829A (en) |
NO (1) | NO854903L (en) |
NZ (1) | NZ211715A (en) |
WO (1) | WO1985004654A1 (en) |
ZA (1) | ZA852629B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU594059B2 (en) * | 1985-05-15 | 1990-03-01 | Biotechnology Australia Proprietary Limited | Oral vaccines |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4736017A (en) * | 1984-04-30 | 1988-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically defined vaccine against urinary infections |
US4584195A (en) * | 1984-06-21 | 1986-04-22 | The Board Of Trustees Of The Leland Stanford Junior University | Broad spectrum vaccine against gonorrhea |
SE8601940D0 (en) * | 1986-04-25 | 1986-04-25 | Kabigen Ab | PREPARATION OF FUSED PROTEINS, ANTIBODIES AND PROCESSES THEREFOR |
AU5403594A (en) * | 1992-10-07 | 1994-04-26 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Pilin variants and uses thereof |
WO1999055875A2 (en) * | 1998-04-29 | 1999-11-04 | American Cyanamid Company | VACCINES CONTAINING RECOMBINANT PILIN AGAINST NEISSERIA GONORRHOEAE OR $i(NEISSERIA MENINGITIDIS) |
US7189405B1 (en) | 1999-10-29 | 2007-03-13 | Rice Peter A | Peptide mimics of conserved gonococcal epitopes and methods and compositions using them |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186182A (en) * | 1975-02-28 | 1980-01-29 | Research Corporation | Serological test for Neisseria gonorrhoeae antibodies |
US4461838A (en) * | 1975-04-25 | 1984-07-24 | Bactex, Inc. | Gonococcal Pili processes for the preparation thereof and the use thereof for the detection of and prevention of infections caused by Neisseria gonorrhoeae |
US4188371A (en) * | 1977-09-28 | 1980-02-12 | Corning Glass Works | Immunological detection of Neisseria bacteria via labelled antibodies |
US4241045A (en) * | 1978-05-15 | 1980-12-23 | Research Corporation | Purified antigen to test for Neisseria gonorrheae antibodies |
US4351761A (en) * | 1978-05-15 | 1982-09-28 | Research Corporation | Purified antigen to test for Neisseria gonorrhoeae antibodies |
US4330623A (en) * | 1980-02-19 | 1982-05-18 | Merck & Co., Inc. | Process for solubilization of gonococcal antigen |
US4386066A (en) * | 1981-08-20 | 1983-05-31 | Merck & Co., Inc. | Immunogenic complex from N. gonorrhoeae |
US4497900A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Neisseria gonorrhoeae antigens |
-
1985
- 1985-04-04 AU AU41590/85A patent/AU582358B2/en not_active Ceased
- 1985-04-04 JP JP60501646A patent/JPS61501777A/en active Pending
- 1985-04-04 WO PCT/US1985/000565 patent/WO1985004654A1/en not_active Application Discontinuation
- 1985-04-04 EP EP19850901876 patent/EP0177583A4/en not_active Withdrawn
- 1985-04-05 IL IL74829A patent/IL74829A/en unknown
- 1985-04-09 ZA ZA852629A patent/ZA852629B/en unknown
- 1985-04-10 NZ NZ211715A patent/NZ211715A/en unknown
- 1985-12-05 NO NO854903A patent/NO854903L/en unknown
- 1985-12-05 FI FI854839A patent/FI81452C/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU594059B2 (en) * | 1985-05-15 | 1990-03-01 | Biotechnology Australia Proprietary Limited | Oral vaccines |
Also Published As
Publication number | Publication date |
---|---|
IL74829A (en) | 1989-02-28 |
FI81452C (en) | 1990-10-10 |
FI81452B (en) | 1990-06-29 |
EP0177583A4 (en) | 1988-06-08 |
NO854903L (en) | 1986-02-04 |
JPS61501777A (en) | 1986-08-21 |
NZ211715A (en) | 1989-01-27 |
FI854839A (en) | 1985-12-05 |
EP0177583A1 (en) | 1986-04-16 |
ZA852629B (en) | 1985-11-27 |
FI854839A0 (en) | 1985-12-05 |
WO1985004654A1 (en) | 1985-10-24 |
IL74829A0 (en) | 1985-07-31 |
AU582358B2 (en) | 1989-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2675009B2 (en) | Improved peptide composition and method for detecting antibodies to HIV | |
JP2682959B2 (en) | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen (diffusion) | |
JPH01501547A (en) | Peptides related to the pathogenesis of HIV infection | |
JP3920320B2 (en) | Purified vacuolating toxin from Helicobacter pylori and method of use thereof | |
JPS62500027A (en) | A chemically synthesized polypeptide that produces antibodies immunoreactive with Epstein-Barr virus nuclear antigens | |
US5445818A (en) | Synthetic pseudomonas aeruginosa pilin peptide vaccine and method of use | |
KR102449695B1 (en) | p72 protein fragment derived from African swine fever virus as recombinant antigen, and uses thereof | |
AU582358B2 (en) | A peptide vaccine or diagnostic, and a polypeptide useful therefor | |
Watts et al. | Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili | |
US5750332A (en) | Peptomers with enhanced immunogenicity | |
KR0151860B1 (en) | Peptides and antibodies derived therefrom for the diagnosis of, therapy for and vaccination against htlv-1 infection | |
US6458922B1 (en) | Antigens and immunoassays for diagnosing Chagas' disease | |
KR20200142460A (en) | p205 protein fragment derived from African swine fever virus as recombinant antigen, and uses thereof | |
Boucher et al. | Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30 | |
JPH04507409A (en) | Rubella E1 peptide | |
US20020081312A1 (en) | Recombinant cryptosporidium parvum antigen and detection of antibodies thereto | |
AU684009B2 (en) | Peptides for diagnostics | |
US6410024B1 (en) | Epitopes of shigella like toxin and their use as vaccine and in diagnosis | |
JPH10506382A (en) | Methods and compositions for differential diagnosis of acute and chronic hepatitis C virus infection | |
KR102433177B1 (en) | p104 protein fragment derived from African swine fever virus as recombinant antigen, and uses thereof | |
EP0470205A1 (en) | New human parvovirus peptides with disulfide bridge for immunization or diagnosis | |
KR20230140889A (en) | p62 protein fragment derived from African swine fever virus as recombinant antigen, and uses thereof | |
KR20230137070A (en) | p30 protein fragment derived from African swine fever virus as recombinant antigen, and uses thereof | |
TWI260347B (en) | Monoclonal antibody of porcine endogenous retrovirus (PERV) capsid, hybridoma generating the antibody, and use thereof | |
KR20230151361A (en) | F20572 fusion fragment derived from African swine fever virus as recombinant antigen, and uses thereof |